Clinical Trial Update: Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and pharmacokinetics of ALMB-0166 in patients with acute spinal cord injury has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• ALMB-0166

Snippet

Sponsor: AlaMab Therapeutics (Shanghai) Inc. | Conditions: Acute Spinal Cord Injury | Phase 1 | Status: COMPLETED